Furthermore, our data on the treatment with Bortezomib (BTZ), a proteasome inhibitor, show a decrease in MTH1 levels in A431 and A388 skin cancer cell lines, correlating with the downregulation of Skp2 (Fig. 4A). Here, SKP2 is linked to skin neoplasm.